Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 1998

View Archived Issues

Novel actions of statins reported at the 20th Congress of the European Society of Cardiology

UC-781: stability in gel formulation, anti-HIV activity

CP-154526, a CRF1 receptor antagonist, reduces stress-induced relapse of drug use in rats

Ribozyme: Q2 1998 highlights

Aviron: Q2 and HY fiscal 1998 highlights

CytRx: Q2 1998 highlights

Texas Biotechnology: Q2 1998 highlights

Purlytin enters development for prostate cancer; another cancer indication abandoned

Licensing and/or CRADA opportunity: drug and method to prevent and treat graft-vs.-host disease

Licensing opportunity from NIH: method of inducing increased resistance to stroke

Potent factor Xa inhibitors from RPR for thromboembolic disorders

Schering AG describes new progestogenic steroids

Nymox discovers new treatment for E. coli 0157:H7 infection

New antibacterial/antitumor agents produced by fungal strains discovered by Kyowa Hakko

Millennium reports advances in the diagnosis, treatment of type II diabetes

Lilly research leads to dual tachykinin antagonists/5-HT agonists

Hoechst increases shareholding in Korean joint venture

Ligand reveals tissue-selective, orally active progestational compound

Broad-spectrum antiviral agents in development at Pfizer

Canadian academic researchers identify estrone sulfatase inhibitors

Gilead announces new clinical trials with GS-1278

Biora: Q2 1998 highlights

Novel lipid-lowering agent presented by Wayne Hughes Institute at scientific forum

Lilly's mGlu agonists exert neuroprotective effects in vivo

Schwarz to market rectal morphine product developed by Core

Pfizer selects GH secretagogue as development candidate

UroCor introduces urine test to identify aggressive bladder cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Peptidream reveals milestone in Alnylam collaboration
BioWorld Science
Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...